Adrian Bot, MD, PhD is the Vice President of Translational Sciences at Kite Pharma Inc, a biotechnology company developing genetically engineered T cell therapies, based in Los Angeles, CA. He has more than 20 years of experience in biomedical research and development.
Dr. Bot obtained his MD at the University of Medicine and Pharmacy in Timisoara, Romania and his PhD in Biomedical Sciences at Mount Sinai School of Medicine in New York. Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla and Scientist, Principal Scientist and Director of Immunology Research at Alliance Pharmaceutical Corp. in San Diego, CA. In Nov 2002, Dr. Bot joined Allecure Pharmaceuticals which became MannKind Corp, where he was a Director of Research and Development. He had several other appointments at MannKind: Sr. Director of Translational Medicine, Vice President of Scientific Management and Vice President of Research, prior to the appointment as Chief Scientific Officer and then Vice President of Translational Sciences at Kite Pharma Inc. Most currently at Kite Pharma, Dr. Bot has been responsible for overseeing the translational activities in support of the development of Axi-Cel, a novel CAR T cell therapy for B cell malignancies. He has been a long time SITC member and is currently serving on the SITC Industry leadership panel.
Dr. Bot’s background is in theoretical and experimental immunology, cancer research, cell therapies, biomolecules and small molecules spanning all stages of development. He authored or co-authored more than 100 research articles, abstracts, reviews, book chapters and monographs in basic and applied immunology. Dr. Bot is the current Editor in Chief of the International Reviews of Immunology and the Section Editor, Immunology and Immunotherapy of the Journal of Translational Medicine.